A Meta-Analysis of Statin Use and Risk of Hepatocellular Carcinoma

Yikai Wang, Wenjun Wang, Muqi Wang, Juanjuan Shi, Xiaoli Jia, and Shuangso Dang

Department of Infectious Diseases, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710004, China

Correspondence should be addressed to Shuangso Dang; dang212@126.com

Received 29 January 2022; Revised 25 February 2022; Accepted 26 February 2022; Published 20 March 2022

Copyright ©2022 Yikai Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The use of statins is a potential protective factor against the development of hepatocellular carcinoma. Therefore, we conducted a meta-analysis to evaluate the contribution of statins to the risk of hepatocellular carcinoma. Methods. We searched for PubMed and EMBASE through January 2021. Results. Thirty-two studies (eighteen cohort, eleven case-control, and three randomized controlled trials) reporting 56,838 cases of hepatocellular carcinoma in 4,963,518 persons were included. Statin users were less likely to develop hepatocellular carcinoma than nonusers (adjusted odds ratio, 0.58; 95% CI: 0.51–0.67). Stratified analysis showed that statins reduced the risk of hepatocellular carcinoma in Asian and Western populations (odds ratio, 0.54 vs. 0.60). Besides, statins have protective effects against hepatocellular carcinoma after hepatitis B virus (odds ratio, 0.44; 95% CI: 0.22–0.85) and hepatitis C virus infections (odds ratio, 0.53; 95% CI: 0.49–0.57). Statins have protective effects on people with chronic liver disease (odds ratio, 0.52; 95% CI: 0.40–0.68) and on the general population (odds ratio, 0.60; 95% CI: 0.50–0.72). Lipophilic statins can prevent hepatocellular carcinoma (odds ratio, 0.51, 95% CI: 0.46–0.57), while hydrophilic statins cannot (odds ratio, 0.77, 95% CI: 0.58–1.02). The single-drug analyses showed that simvastatin (odds ratio, 0.53, 95% CI: 0.48–0.59), atorvastatin (odds ratio, 0.54, 95% CI: 0.45–0.64), rosuvastatin (odds ratio, 0.55, 95% CI: 0.37–0.83), lovastatin (odds ratio, 0.30, 95% CI: 0.15–0.62), and pitavastatin (odds ratio, 0.36, 95% CI: 0.17–0.75) had significant benefits. Further studies have shown that those in the high-dose group experienced better effects in preventing hepatocellular carcinoma (adjusted hazard ratio, 0.38 vs. 0.55). Further research found that the combined use of aspirin did not increase the chemoprevention effect of liver cancer (odds ratio, 0.57; 95% CI: 0.40–0.81). In addition, the preventive effect of statins improved with the extension of follow-up time (odds ratio, 0.54 vs. 0.65). Conclusion. Our meta-analysis shows that the use of statins is associated with a lower risk of liver cancer.

1. Introduction

Liver cancer is one of the most common cancers in the world, imposing substantial burdens on patients and society [1, 2]. Traditional treatment methods such as surgical resection, liver transplantation, and chemotherapy also have a good curative effect in the early stage of cancer. With the emergence of targeted drugs such as sorafenib, a new approach has been brought to the treatment of liver cancer. In recent years, immunotherapy has gradually emerged, especially the use of inhibitors targeting immune checkpoints, PD1, PDL1, and CTLA4, showing a good therapeutic prospect. However, when 70% of liver cancer patients go to a doctor, the disease has progressed to the middle and late stages [3], so it is still particularly important to prevent the occurrence and progression of liver cancer. However, there is still no preventive drug that can reduce the risk of liver cancer. Statins are mostly used to prevent and control cardiovascular diseases [4] and reduce plasma cholesterol levels [5]. In addition, increasing attention has been given to statins because of their anticancer effects [6, 7] on prostate cancer [8], colorectal cancer [9], and hepatocellular carcinoma (HCC) [10–12]. Previous investigations have shown that statins have the potential chemopreventive effects on liver cancer [13] in vivo and in vitro, mainly by inhibiting angiogenesis, tumor growth, and metastasis and inducing
apoptosis [14–16]. However, some studies did not show any beneficial effects [17].

Accordingly, our group conducted this meta-analysis to evaluate the relationship between statin use and the risk of liver cancer; this updated meta-analysis has the benefits of including recently published studies and more subgroup analyses.

2. Methods

2.1. Subjects. The meta-analysis is reported based on the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) checklist [18], following the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines (ID: CRD42021268397). No ethics issues were involved in this research because our data were obtained from published studies.

2.2. Included Index Classifications. Randomized controlled trials (RCT), cohort studies, nested case-control studies, and case-control studies were included in this meta-analysis. The patients included were adults (18 years or older) who were ultimately diagnosed with liver cancer (diagnosed using any recognized diagnostic criteria), regardless of sex or race. In addition, the interventions were defined as any dose, route of administration, and duration of statin therapy (including fluvastatin, pravastatin, rosuvastatin, simvastatin, lovastatin, pitavastatin, atorvastatin, and cerivastatin). The control group could be a placebo or a nonstatin therapy.

Studies were excluded if they were animal experiments, reviews, meta-analyses, editorials, and published letters.

2.3. Treatment of Results. The risk of HCC in statin users was assessed first. We use the odds ratio (OR) to evaluate the risk of HCC. When the OR was less than 1, the use of statins had a protective effect against the occurrence of HCC. To explain the potential heterogeneity, experimental design, experimental location, etiology, presence of chronic liver disease, type of statins, and dosage of statins were investigated.

2.4. Search Strategy. Two electronic databases containing articles published in English, namely, PubMed and EMBASE, were thoroughly searched to identify the studies that could be included in the analysis. Based on the guidance in the Cochrane handbook, we developed detailed strategies, including "statin" [MeSH term] or "statin" or "atorvastatin" or "fluvastatin" or "cerivastatin" or "lovastatin" or "pravastatin" or "rosuvastatin" or "simvastatin" or "pitavastatin" or "HMG-CoA reductase inhibitors" and "hepatocellular carcinoma" [MeSH terms] or "liver neoplasms" [MeSH term] or "liver cancer" or "HCC." The reference lists of the studies included and related reviews were manually checked to identify other citations. To ensure that the qualified studies were correctly identified, two researchers independently read each report, and all the researchers resolved their differences by reaching consensus. The flowchart summarizing the study selection process is shown in Figure 1.

2.5. Data Extraction and Quality Evaluation. Data were extracted from all eligible studies by 2 independent researchers (Yikai Wang and Wenjun Wang). The following data were collected from each study: study design, country of origin of the study population, time period of the study, number of people included, outcome events, and adjusted confounding factors.

Data on the following confounding HCC risk factors were extracted from each study: age, sex, race, socioeconomic status, body mass index (BMI), diabetes (DM), the presence of cirrhosis, hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, presence of alcoholic liver disease, and the use of angiotensin-converting enzyme inhibitors/nonsteroidal anti-inflammatory drugs/aspirin/metformin/proton pump inhibitors (PPIS)/nonstatin lipid-lowering drugs and lifestyle habits (Tables 1 and 2).

We used the Cochrane intervention system evaluation manual V.5.1.0 to evaluate the quality of RCTs. The risk of bias tool covers seven aspects: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. In the end, we classified each RCT into one of three levels: high risk, low risk, and unclear risk of bias. The results of the risk assessment are shown in Figure 2.

The quality of observational research was assessed using the Newcastle–Ottawa scale, which is one of the most commonly used rating systems for evaluating the quality of observational research in meta-analyses [19]. The scale is based on a star allocation system, in which up to nine stars are allocated based on the risk of bias in the three covered areas. Each study is scored according to the following three items: patient selection (four stars), comparability of study groups (two stars), and results/exposure assessment (three stars). The star rating system can be used to indicate the quality of each study. Fewer than seven stars indicate low quality, and more than seven stars indicate high quality. Two reviewers independently evaluated the risk of bias in the included studies. If there were any differences in their evaluations, a consensus was reached through group discussion and negotiation. If we had unresolvable questions, we directly asked the author.

2.6. Statistical Analysis. We considered $P < 0.05$ to indicate statistical significance, and all statistical tests were two-sided. For statistical analysis, we chose the commonly used software Review Manager (RevMan v5.4, Copenhagen). To obtain a more generalizable result, we used the random-effects model for the meta-analysis of the OR data because all potential heterogeneities were included in the construction of model [20]. By analyzing the adjusted OR (for case-control studies) in this study, the confounding variables were accounted for to a certain extent.
We used the $I^2$ and Cochran’s $Q$ tests to evaluate heterogeneity, as these are often used to measure inconsistency among different studies. If the $I^2$ value was $>50\%$ or $P < 0.10$, the heterogeneity was considered significant [21]. We used STATA 16.0 to draw a funnel plot and perform an Egger’s regression asymmetry test.

### 3. Results

#### 3.1. Search Results

We selected 638 and 1,453 articles from PubMed and EMBASE, respectively. After applying the inclusion criteria and deleting duplicate studies, 30 studies were finally selected for inclusion in the meta-analysis [17, 22–49]. In a total of 4,963,518 people, these studies reported 56,838 cases of HCC. Of the RCTs selected for the analysis included two prospective controlled trials of atherosclerotic heart disease, and these patient data were included in the analysis [47, 48]. Among the included studies, the cohort study conducted by Friedman et al. [33] gave the OR estimates for men and women separately, so we treated these datasets as two independent studies in the analysis.

#### 3.2. Characteristics of Included Studies

The characteristics of these studies are shown (Table 1). Nineteen studies were cohort studies, ten studies were retrospective case-control studies, and three studies were RCTs. The study by Tran et al. contained a nested case-control and a prospective cohort, so we analyzed the two cohorts separately. In Friedman’s article, we calculated the values stratified by sex.

Nine articles were from Asia, including two from China (one from Taiwan and one from Hong Kong), five from Korea, and two from Japan. Twenty-two articles were from Western countries, including eleven from the United States, four from the United Kingdom, three from Switzerland, one from Denmark, and one from Italy. One RCT was a multicenter study from Europe, Australia, and South America. Taking into account the differences among ethnicities, we conducted a subgroup analysis in the follow-up analysis. The study population variables used for adjustment were age, sex, etiology of the potential liver disease, other complications, and the use of other drugs.

#### 3.3. Quality of Included Studies

The median Newcastle–Ottawa scale score was seven (range, 5–9); eighteen of the thirty studies were considered to be of high quality. The methodological quality of all studies is described (Table 1). Most studies were adjusted for the following confounding factors: age (21/30), sex (22/30), diabetes (18/30), medications (17/30), alcoholic liver disease (16/30), viral hepatitis (13/30), and cirrhosis (12/30) (Tables 1 and 2).

#### 3.4. Risk of HCC

In the meta-analysis assessing the risk of HCC, the use of statins was related to a significant 42% reduction in the incidence of HCC (Figure 3). There was substantial heterogeneity (Cochran’s $Q$ test $P < 0.00001$, $I^2 = 99\%$). The shape of the funnel plot indicated that there was a low significant publication bias (Figure 4). Results of Egger’s regression test also suggested a low possibility of publication bias ($P = 0.064$) (Figure 4).

#### 3.5. Subgroup Analyses

Based on the predetermined assumptions, we conducted a hierarchical analysis according to the study design (Table 3). An analysis of the twenty-eight articles identified through literature searches = PubMed (n=638) EMBASE (n=1453)

Studies remaining after duplicates removed (1837)

Full-text articles reviewed (609)

Full-text articles assessed for potential eligibility (145)

Articles included in the meta-analysis (29)

Articles excluded based on abstracts (1228)

Articles excluded because they were: nonhuman studies (205) reviews (147) meta-analyses (46) editorials (26) published letters (36) Lacking an available full-text version (4)

Figure 1: Flow diagram summarizing study identification and selection.

Table 1: Characteristics and quality of included studies assessing the risk of HCC with statin use.

| Study                        | Design | Location     | Setting                  | Time period | Total no. of subjects | No. of HCC cases | Variables adjusted for | Study quality | Outcome/exposure |
|------------------------------|--------|--------------|--------------------------|-------------|-----------------------|-----------------|------------------------|---------------|------------------|
| **Observational studies**    |        |              |                          |             |                       |                 |                        |               |                  |
| Karl et al. (2019)           | Cohort | Swedish      | Population based         | 1998–2012   | 2,440,620             | 2742            | 1, 2, 7, 9, 12, 13, 18, 21 | ***           | **               |
| Friis et al. (2005)          | Cohort | Danish       | Population based         | 1989–2002   | 348,262               | 171             | 1, 2, 9, 25            | **            | **               |
| Tsan et al. (2013)           | Cohort | Taiwan       | Population based         | 1999–2010   | 260,864               | 27883           | 1, 2, 5, 7, 11         | ***           | **               |
| Butt et al. (2015)           | Cohort | United States| Population based         | 2002–2013   | 7248                  | 141             | 16                      | **            | **               |
| Simon et al. (2016)          | Cohort | United States| Population based         | 2001–2014   | 9,135                 | 233             | 1, 2, 4, 6, 7, 8, 9, 10, 12, 13, 16, 22, 26 | ***           | **               |
| Friis et al. (2005)          | Cohort | Denmark      | Population based         | 2002–2013   | 9,852                 | 1642            | 1, 2, 3, 4, 5, 6, 7, 12, 13, 21, 28 | **            | ***              |
| Tsan et al. (2013)           | Cohort | Taiwan       | Population based         | 2004–2007   | 400,318               | 1686            | 1, 2, 3, 4, 5, 6, 7, 12, 13, 21, 28 | **            | **               |
| Butt et al. (2015)           | Cohort | United States| Population based         | 2001–2014   | 9,135                 | 233             | 1, 2, 4, 6, 7, 8, 9, 10, 12, 13, 16, 22, 26 | ***           | **               |
| Simon et al. (2016)          | Cohort | United States| Population based         | 2001–2014   | 9,135                 | 233             | 1, 2, 4, 6, 7, 8, 9, 10, 12, 13, 16, 22, 26 | ***           | **               |
| Kim et al. (2017)            | Cohort | United States| Population based         | 2008–2012   | 7,713                 | 702             | 1, 2, 3, 4, 5, 6, 7, 12, 13, 16, 22, 26 | **            | **               |
| Kim et al. (2016)            | Cohort | United States| Population based         | 2008–2012   | 7,713                 | 702             | 1, 2, 3, 4, 5, 6, 7, 12, 13, 16, 22, 26 | **            | **               |
| El-Serag et al. (2009)       | Cohort | United States| Population based         | 1997–2007   | 6,515                 | 1303            | 3, 4, 5, 6, 7, 9, 10, 12, 13, 16, 22, 26 | **            | **               |
| McGlynn et al. (2015)        | Cohort | United States| Population based         | 2008–2012   | 5,835                 | 1244            | 1, 2, 3, 4, 5, 6, 7, 12, 13, 16, 22, 26 | **            | **               |
| Tran et al. (2019)           | Cohort | United States| Population based         | 2004–2007   | 91,714                | 105             | 1, 2, 3, 4, 5, 6, 7, 12, 13, 16, 22, 26 | **            | **               |
| Marelli et al. (2011)        | Cohort | United States| Population based         | 2008–2012   | 5,357                 | 19 NR            | 1, 2, 3, 4, 5, 6, 7, 12, 13, 16, 22, 26 | **            | **               |
| Friedman et al. (2014)       | Cohort | United States| Population based         | 1997–2007   | 6,515                 | 1303            | 3, 4, 5, 6, 7, 9, 10, 12, 13, 16, 22, 26 | **            | **               |
| Hsiang (2015)                | Cohort | Hong Kong    | Population based         | 2008–2012   | 53,513                | 6883            | 1, 2, 3, 4, 5, 6, 7, 12, 13, 16, 22, 26 | **            | **               |
| Mohanty (2016)               | Cohort | United States| Population based         | 1996–2009   | 40,512                | 173             | 1, 2, 3, 4, 5, 6, 7, 12, 13, 16, 22, 26 | **            | **               |
| Björkhem-Bergman (2014)      | Cohort | Sweden       | Population based         | 2006–2010   | 23,964                | 3994            | 1, 2, 3, 4, 5, 6, 7, 9, 12, 13, 16, 22, 26 | **            | **               |
| Friedman et al. (2016)       | Cohort | United States| Population based         | 2006–2010   | 23,964                | 3994            | 1, 2, 3, 4, 5, 6, 7, 9, 12, 13, 16, 22, 26 | **            | **               |
| McGlynn et al. (2014)        | Cohort | United States| Population based         | 2006–2010   | 23,964                | 3994            | 1, 2, 3, 4, 5, 6, 7, 9, 12, 13, 16, 22, 26 | **            | **               |
| German et al. (2020)         | Cohort | United States| Population based         | 2006–2010   | 23,964                | 3994            | 1, 2, 3, 4, 5, 6, 7, 9, 12, 13, 16, 22, 26 | **            | **               |
| Galli et al. (2014)          | Cohort | Italy        | Population based         | 1991–2012   | 5357                  | 19 NR           | 1, 2, 3, 4, 5, 6, 7, 9, 12, 13, 16, 22, 26 | **            | **               |
| Kumar et al. (2013)          | Cohort | United States| Population based         | 1998–2011   | 243                   | 29              | 1, 2, 3, 4, 5, 6, 7, 9, 12, 13, 16, 22, 26 | **            | **               |
| McGlynn et al. (2016)        | Cohort | United States| Population based         | 2008–2016   | 74,984                | 2420            | 1, 2, 3, 4, 5, 6, 7, 9, 12, 13, 16, 22, 26 | **            | **               |
| Kim et al. (2016)            | Cohort | United States| Population based         | 2008–2016   | 74,984                | 2420            | 1, 2, 3, 4, 5, 6, 7, 9, 12, 13, 16, 22, 26 | **            | **               |
| Kaplan et al. (2019)         | Cohort | United States| Population based         | 2008–2016   | 74,984                | 2420            | 1, 2, 3, 4, 5, 6, 7, 9, 12, 13, 16, 22, 26 | **            | **               |
| Simon et al. (2019)          | Cohort | Swedish      | Population based         | 2005–2013   | 16,668                | 1012            | 1, 2, 3, 4, 5, 6, 7, 9, 12, 13, 16, 22, 26 | **            | **               |

**RCTs**

Canadian Journal of Gastroenterology and Hepatology
observational studies showed that the use of statins reduced the incidence of liver cancer by 43%, although the heterogeneity among the studies was large. In addition, in three studies containing data from multiple RCTs, statins did not have protective effects, although no significant heterogeneity was found in this group. This suggests that the heterogeneity of the article may be mainly concentrated on observational research.

According to the subgroup analysis stratified by geographic location, the use of statins significantly reduced the risk of HCC by 46% in Asian populations (OR, 0.54; 95% CI: 0.42–0.70) and by 40% (OR, 0.60; 95% CI: 0.51–0.71) in Western populations (although there was even greater heterogeneity). Unfortunately, these two subgroup analyses did not explain the significant heterogeneity in the overall analysis.

Next, the protective effect of statins against liver cancer caused by HBV and HCV infections was evaluated. It was confirmed that the use of statins in HBV-positive patients had a significant preventive effect against HCC (OR, 0.44, 95% CI: 0.22–0.85; \( I^2 = 65% \)). Moreover, HCV-positive patients also experienced clear preventive effects (OR, 0.53, 95% CI: 0.49–0.57; \( I^2 = 79% \)), and no heterogeneity was found.

After classifying the population included in the study, statins had obvious preventive effects in people with chronic liver disease (OR, 0.52, 95% CI: 0.40–0.68). However, the protective effect of statins in the general population is slightly lower than that of patients with chronic liver disease (OR, 0.60, 95% CI: 0.50–0.72).

Lipophilic statins (simvastatin, atorvastatin, fluvastatin, lovastatin, pitavastatin, and cerivastatin) were associated with a significant reduction in the incidence of HCC (OR, 0.51, 95% CI: 0.46–0.57; \( I^2 = 23% \)). However, we did not find an association between hydrophilic statin drugs (pravastatin and rosuvastatin) and a reduction in the risk of liver cancer (OR, 0.77, 95% CI: 0.58–1.02; \( I^2 = 45\% \)). Single-drug analyses showed that simvastatin (OR, 0.53, 95% CI: 0.48–0.59; \( I^2 = 0\% \)), atorvastatin (OR, 0.54, 95% CI: 0.45–0.64; \( I^2 = 0\% \)), rosuvastatin (OR, 0.55, 95% CI: 0.37–0.83; \( I^2 = 0\% \)), lovastatin (OR, 0.30, 95% CI: 0.15–0.62; \( I^2 = 0\% \)), and pitavastatin (OR, 0.36, 95% CI: 0.17–0.75; \( I^2 = 0\% \)) had significant benefits, with moderate heterogeneity. However, we found no benefit of fluvastatin (OR, 0.83, 95% CI: 0.48–1.44; \( I^2 = 10\% \)), pravastatin (OR, 0.77, 95% CI: 0.57–1.05; \( I^2 = 0\% \)), or cerivastatin (OR, 0.61, 95% CI: 0.26–1.42; \( I^2 = 0\% \)).

Analysis of the magnitude of statin chemoprophylaxis showed a linear correlation with the dose, with AHRs of 0.55 (95% CI: 0.47–0.65) and 0.38 (95% CI: 0.28–0.50), respectively, in patients receiving cumulative defined daily doses (CDDDs) less than or greater than 365 (Table 3).

Next, we further explored the effect of coadministration of aspirin on the effect of statins on the prevention of hepatocellular carcinoma. Concomitant use of aspirin did not significantly improve the chemopreventive effect of statins (OR, 0.57; 95% CI: 0.40–0.81). In addition, aspirin alone has no chemopreventive effect on the occurrence of liver cancer (OR, 0.86; 95% CI: 0.65–1.14).

In addition, we discussed the incidence of liver cancer in the population within 10 years of follow-up and those with more than 10 years of follow-up, respectively. Interestingly, we found a lower incidence of liver cancer in the population over 10 years (OR, 0.54 vs. 0.65).

### 3.6. Sensitivity Analyses

Sensitivity analyses were conducted based on study design and quality to identify the source of the heterogeneity in observational studies (Table 4). The chemopreventive effect of statins against liver cancer was

### Table 1: Continued.

| Study              | Design | Location       | Setting                                  | Time period | Total no. of subjects | No. of HCC cases | Variables adjusted for | Selection | Comparability | Outcome/exposure |
|--------------------|--------|----------------|------------------------------------------|-------------|-----------------------|------------------|------------------------|-----------|---------------|------------------|
| Matsushita et al. (2010) | RCT    | Japan          | Individual patient data analysis of trials | 2010        | 13,724                | 12               | NR                     | ****      | **            | *                |
| CTT (2012)         | RCT    | Europe, Australia, North America | Individual patient data analysis of trials | 2012        | 134,537               | 68               | NR                     | ****      | **            | **               |
| Sato et al. (2006)  | RCT    | Japan          | Secondary analysis of RCT                 | 1991–1995   | 263                   | 1                | 1, 2, 13               | **        | **            | *                |

N/A, not applicable. *1, age; 2, sex; 3, HBV; 4, HCV; 5, cirrhosis; 6, alcoholic liver disease/ulcer use; 7, diabetes mellitus; 8, race; 9, other medications (aspirin/nonsteroidal anti-inflammatory medications, angiotensin-converting enzyme inhibitors, metformin, antidiabetic medications, PPIs, H2RAs, antihypertension medications, paracetamol, insulin, thiazolidinediones, and sulfonylurea); 10, other lipid-lowering agents; 11, socioeconomic status; 12, body mass index; 13, smoking; 14, comorbidities; 15, calendar year; 16, FIB-4 score; 17, other liver disease etiology; 18, hypertension; 19, dyslipidemia/hyperlipidemia/hypercholesterolemia; 20, CCI index; 21, complete biochemical tests; 22, education level; 23, antiviral therapy/attainment of SVR; 24, obesity; 25, MELD score; 26, hormone replacement therapy; 27, the presence of nonhemorrhagic varices; 28, physical activity; 29, follow-up duration; 30, gout; 31, rare metabolic disorders; 32, biochemical indicators; 33, family history of liver disease; 34, previous cancer; 35, pulmonary disease; 36, history of substance abuse; 37, center characteristics. *Study quality assessment of observational studies was performed using the Newcastle–Ottawa scale; each asterisk represents if an individual criterion within the subsection was fulfilled.
Table 2: Comparison of reported baseline risk factors for HCC and analysis of potential confounders in included studies.

| Study               | Age (y) | Sex (% male) | Diabetes (% total) | Cirrhosis (% total) | HBV/HCV (% total) | Alcoholic liver disease or alcohol use (% total) | Angiotensin-converting enzyme inhibitor/nonsteroidal anti-inflammatory drug/aspirin (% total) | Nonstatin lipid-lowering drug (% total) |
|---------------------|---------|--------------|--------------------|---------------------|-------------------|------------------------------------------------|----------------------------------------------------------------------------------|----------------------------------|
| Karl et al. (2019)  | NR      | NR           | 57                 | 50                  | NR                | NR                                              | NR/80/NR/48                                                                      | NR                               |
| Friis et al. (2005) | 60.7    | 46.6         | 57                 | 50                  | NR                | NR                                              | 8.8/11.5                                                                        | NR                               |
| Tsan et al. (2013)  | 53.9    | 49.8         | 49.8               | 50.2                | NR                | NR                                              | 53.9/81.4/58.9                                                                  | 6.6/0.5                          |
| Butt et al. (2015)  | 53      | 52           | 96.4               | 94.9                | 22.1              | 6.8                                             | 17.3/25.2                                                                       | NR                               |
| Simon et al. (2016) | 53      | 52.5         | 96.16              | 95.37               | 24.03             | 8.87                                            | 14.02/21.43                                                                     | NR                               |
| Kim et al. (2017)   | 61.8    | 61.8         | 83.6               | 83.6                | 18.6              | 11.2                                            | 34.2/1.1                                                                         | NR                               |
| Yi et al. (2019)    | 50      | 47           | 67.6               | 66.1                | 39.6              | 10.9                                            | 25.1/100/NR                                                                     | NR                               |
| Goh et al. (2019)   | 50      | 47           | 67.6               | 66.1                | 39.6              | 10.9                                            | 25.1/100/NR                                                                     | NR                               |
| El-Serag et al. (2009) | 72    | 72           | 99                 | 99                  | 100               | 100                                            | 28.2/1.6                                                                         | 16.5/1.2                         |
| McGlynn et al. (2015) | 67.2 | 67           | 71.6               | 71.6                | 29                | 10                                             | 6.2/0.1                                                                          | 15.8/4                           |
| Tran et al. (2019)* | NR      | 67.3         | 67.1               | 12.2                | 4.2               | NR                                              | 55.7/56.9                                                                        | NR                               |
| Tran et al. (2019)  | NR      | 62.6         | 64.1               | 19.2                | 5                 | NR                                              | 83.5/91.7                                                                        | NR                               |
| Marelli et al. (2011)| 64.2  | 64.2         | 52.2               | 52.6                | 16.1              | 15.8                                            | NR/0.06                                                                         | —/28.4/19.4/23.6                  |
| Friedman et al. (2008)* | NR   | NR           | NR                 | NR                  | NR                | NR                                              | 52.5/56.6                                                                        | NR                               |
| Hsiang (2015)       | 58.7    | 37.6         | 67.9               | 25.5                | 45.1              | 7.4                                             | NR/2.7                                                                          | NR                               |
| Mohanty (2016)      | 56      | 54           | 98.3               | 97.7                | 54.8              | 28.9                                            | NR/1.6                                                                          | NR                               |
| Björkhem-Bergman (2014) | NR   | 52           | 52                 | NR                  | NR                | NR                                              | NR/9.3                                                                          | NR                               |
| Friedman (2016)     | NR      | NR           | NR                 | NR                  | NR                | NR                                              | NR/2.1                                                                          | NR                               |
| McGlynn (2014)      | NR      | NR           | NR                 | NR                  | NR                | NR                                              | NR/1.6                                                                          | NR                               |
| German et al. (2020) | 64.3  | 65.2         | 64.7               | 64.7                | 64.7              | 76.5                                            | NR/26.5/41.2/48.5                                                                | NR                               |
| Yang et al. (2013)  | NR      | NR           | NR                 | NR                  | NR                | NR                                              | NR/26.5/41.2/48.5                                                                | NR                               |
| Galli et al. (2014) | 51.1    | 45.7         | 80                 | 76                  | 100               | 100                                            | 2.47/6.17                                                                       | NR                               |
| Kumar et al. (2013) | 59.7    | 59.6         | 54.32              | 54.32               | 55.56             | 30.86                                          | 22.2/33.9                                                                       | NR                               |
| McGlynn et al. (2016) | 68.1  | 67.9         | NR                 | 17.1                | 7.98              | NR                                              | NR/2.1                                                                          | NR                               |
| Kim et al. (2016)   | NR      | NR           | 81.4               | 81.4                | 100               | 100                                            | 2.1/0.1                                                                        | NR/1.4                           |
| Kim et al. (2019)   | 55.4    | 51.8         | 41.1               | 51.8                | 0                 | 0                                              | 100/0/100                                                                      | NR/11.8/8.7                      |
| Kaplan et al. (2019) | 64    | NR           | 97.5               | NR                  | 70.8              | 40.6                                            | NR/11.2/29.2                                                                    | NR                               |
| Simon et al. (2019) | NR      | NR           | 65.6               | 34.8                | 32.8              | 30.5                                            | NR/35.5/36.0                                                                    | NR                               |
| Matsushita et al. (2010) | 57.9 | 57.1         | 52.6               | 50.5                | 19.7              | 21.5                                            | NR/14.4                                                                        | NR                               |
| CTT (2012)          | 63      | 71           | NR                 | NR                  | NR                | NR                                              | NR/14.4                                                                        | NR                               |
| Sato et al. (2006)  | NR      | NR           | 81.7               | NR                  | NR                | NR                                              | NR/14.4                                                                        | NR                               |

Note: for case-control study design, case refers to patients with HCC and control refers to patients without HCC; for cohort study design, case refers to statin users and control refers to statin nonusers. NR, not reported. *Data source: the primary care clinical informatics unit (PCCIU) database. †Data source: the UK Biobank. Separate analyses of male and female subjects.
Random sequence generation (selection bias)
CTT 2012
Matsushita et al 2010
Sato et al 2006
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias

Figure 2: Quality of the RCT articles.

| Study or Subgroup                  | log [Odds Ratio] | SE  | Weight | Odds Ratio IV, Random, 95% CI | Odds Ratio IV, Random, 95% CI |
|------------------------------------|------------------|-----|--------|-------------------------------|-------------------------------|
| Björkhem-Bergman 2014              | -0.1278          | 0.0423 | 4.9%   | 0.88 [0.81, 0.96]             |                               |
| Butt et al 2015                    | -0.6539          | 0.202  | 3.6%   | 0.52 [0.35, 0.77]             |                               |
| CTT 2012                           | 0.0592           | 0.243  | 3.2%   | 1.06 [0.66, 1.71]             |                               |
| El-Serag et al 2009                | -0.3011          | 0.0741  | 4.7%   | 0.74 [0.64, 0.86]             |                               |
| Friedman 2016                      | -0.8916          | 0.0807  | 4.7%   | 0.41 [0.35, 0.48]             |                               |
| Friedman et al - male 2008         | -0.7133          | 0.1865  | 3.7%   | 0.49 [0.34, 0.71]             |                               |
| Friedman et al female 2008         | -0.9163          | 0.3288  | 2.4%   | 0.40 [0.21, 0.76]             |                               |
| Friis et al 2005                   | 0.1484           | 0.4719  | 1.6%   | 1.16 [0.46, 2.93]             |                               |
| Galli et al 2014                   | -0.9163          | 0.3537  | 2.3%   | 0.40 [0.20, 0.80]             |                               |
| German et al 2020                  | -1.6094          | 0.5356  | 1.3%   | 0.20 [0.07, 0.57]             |                               |
| Goh et al 2019                     | -1.0217          | 0.3261  | 2.5%   | 0.36 [0.19, 0.68]             |                               |
| Hsiang 2015                        | -0.3857          | 0.1777  | 3.8%   | 0.68 [0.48, 0.96]             |                               |
| Kaplan et al 2019                  | -0.0608          | 0.033   | 4.9%   | 0.94 [0.88, 1.00]             |                               |
| Karl et al 2019                    | -0.478           | 0.1413  | 4.2%   | 0.62 [0.47, 0.82]             |                               |
| Kim et al 2016                     | -1.0217          | 0.2513  | 3.1%   | 0.36 [0.22, 0.59]             |                               |
| Kim et al 2017                     | -0.821           | 0.1468  | 4.1%   | 0.44 [0.33, 0.59]             |                               |
| Kim et al 2019                     | -1.772           | 0.7382  | 0.8%   | 0.17 [0.04, 0.72]             |                               |
| Kumar et al 2013                   | -0.1165          | 0.4342  | 1.8%   | 0.89 [0.38, 2.08]             |                               |
| Marelli et al 2011                 | -0.1393          | 0.1896  | 3.7%   | 0.87 [0.60, 1.26]             |                               |
| Matsushita 2010                    | -0.5447          | 0.597   | 1.1%   | 0.58 [0.18, 1.87]             |                               |
| McGlynn 2014                       | -1.1394          | 0.3866  | 2.0%   | 0.32 [0.15, 0.68]             |                               |
| McGlynn et al 2015                 | -0.5978          | 0.1024  | 4.5%   | 0.55 [0.45, 0.67]             |                               |
| McGlynn et al 2016                 | -0.1393          | 0.1728  | 3.9%   | 0.87 [0.62, 1.22]             |                               |
| Mohanty 2016                       | -0.8675          | 0.2254  | 3.3%   | 0.42 [0.27, 0.65]             |                               |
| Sato et al 2006                     | -0.462           | 0.8735  | 0.6%   | 0.63 [0.11, 3.49]             |                               |
| Simon et al 2016                   | -0.6733          | 0.1777  | 3.8%   | 0.51 [0.36, 0.72]             |                               |
| Simon et al 2019                   | -0.734           | 0.0681  | 4.8%   | 0.48 [0.42, 0.55]             |                               |
| Tran et al 2019*                   | -0.4943          | 0.1784  | 3.8%   | 0.61 [0.43, 0.87]             |                               |
| Tran et al 2019*                   | -0.734           | 0.3537  | 2.3%   | 0.48 [0.24, 0.96]             |                               |
| Tsan et al 2013                     | -0.6349          | 0.04    | 4.9%   | 0.53 [0.49, 0.57]             |                               |
| Yi et al 2019                       | 0.1484           | 0.1896  | 3.7%   | 1.16 [0.80, 1.68]             |                               |

Total (95% CI) 100.0% 0.58 [0.51, 0.67]

Heterogeneity: Tau^2 = 0.10; chisq = 309.52, df = 30 (P < 0.00001); I^2 = 90%
Test for overall effect: Z = 7.45 (P < 0.00001)

Figure 3: Statin and risk of hepatocellular carcinoma—adjusted OR.
confirmed in case-control studies and cohort studies, and there was no significant difference between the groups. In the analysis based on research quality, both high-quality research and low-quality research studies have protective effects, but there is no significant difference between the two (Table 4). However, high-quality research has significant heterogeneity ($I^2 = 94\%$).

Through the analysis of research sites of high-quality observational research, it is found that Asian research has no obvious heterogeneity ($I^2 = 44\%$), while Western research has significant heterogeneity ($I^2 = 92\%$). Therefore, this explains to a certain extent that the overall heterogeneity of the article comes from high-quality Western observational research (Table 4).

4. Discussion

Through a comprehensive meta-analysis of all existing studies of more than 56,838 HCC patients, we found that after adjusting for confounding variables, the use of statins significantly reduces the risk of HCC by 42%. In our meta-analysis, the possibility of selection or publication bias was low, and all included articles did not meet the exclusion criteria. This meta-analysis showed that long-term use of statin can reduce the incidence of HCC, which is consistent with the previous six meta-analysis [12, 50–54]. Statins are 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitors that have long been used for the treatment of dyslipidemia and cardiovascular diseases. In recent years, there have been an increasing number of experimental studies on statins as potential anticancer drugs. A number of studies have shown that statins have immunomodulatory properties, antiproliferative properties that regulate cell cycle regulatory proteins, proapoptotic properties, and antiinvasive properties [4, 55–57]. Studies have shown that statins exert the antitumor effect through the dependent/independent HMG-CoA reductase pathway. Statins competitively inhibit HMG-CoA reductase, block the conversion of HMG-CoA to mevalonate, and inhibit the production of several downstream molecules, including isoprenoid. Studies have shown that statins can not only lower cholesterol but also inhibit the proliferation of cancer cells by reducing the production of isoprene (a posttranslational modification of RAS protein) [58]. Furthermore, this effect of statins was independent of its lipid-lowering effects because nonstatin lipid-lowering agents were not associated with reduction in the risk of HCC [17, 59].

In addition, chronic liver damage is also an essential factor affecting the progression of HCC [60]. Liver inflammation is mainly caused by c-Fos expressed in liver cells, and the recruited immune cells are primarily granulocytes. The main triggers of this process may be chronic damage to liver cells caused by the accumulation of oxysterols, cholesterol, and primary alkaline phosphatase. Statins can induce the secretion of IL-6, IL-1β, tumor necrosis factor, reactive oxygen species (ROS), and other molecules that mediate inflammatory damage, thereby further inducing hepatocyte apoptosis [61]. However, statins can inhibit the expression of TNF-α and IL-6 and significantly reduce ROS production and metalloproteinase activity, thereby reducing liver inflammation [62, 63]. Relevant studies have shown that the use of statins in c-Fos hep-tetOFF mice can reduce liver inflammation [64]. The activation of MYC is very important in the tumorigenesis of liver cancer, and its inactivation can lead to the continuous regression of HCC [65, 66].
In human hepatocarcinoma cell lines and aflatoxin-induced liver cancer transgenic animal models, atorvastatin has been shown to block phosphorylation and activation of Myc through HMG-CoA reductase-dependent pathways, thereby inhibiting tumorigenesis and tumor growth [57]. Statins can induce cell apoptosis, but the underlying pathway has not been fully confirmed. Statins may block the

---

**Table 3: Subgroup analysis to examine sources of heterogeneity observed in summary estimate.**

| Subgroup analysis                  | No. of studies | Adjusted OR | 95% CI       | Tests of heterogeneity  |
|-----------------------------------|----------------|-------------|--------------|-------------------------|
|                                   |                |             |              |  \( P \) | \( I^2 (%) \) | Heterogeneity between groups (\( P \)) |
| Study design                      |                |             |              |                        |                                      |
| Observational                     | 28             | 0.57        | 0.49–0.66    | <0.00001               | 91                                    |
| RCT                               | 3              | 0.95        | 0.62–1.45    | 0.57                   | 0                                     |
| Study location                    |                |             |              |                        |                                      |
| Asian                             | 9              | 0.54        | 0.42–0.70    | 0.0008                 | 70                                    |
| Western                           | 22             | 0.60        | 0.51–0.71    | <0.00001               | 90                                    |
| Etiology of liver disease         |                |             |              |                        |                                      |
| HBV                               | 3              | 0.44        | 0.22–0.85    | 0.06                   | 65                                    |
| HCV                               | 4              | 0.53        | 0.49–0.57    | 0.79                   | 0                                     |
| Chronic liver disease             |                |             |              |                        |                                      |
| Yes                               | 11             | 0.52        | 0.40–0.68    | <0.00001               | 95                                    |
| No                                | 18             | 0.60        | 0.50–0.72    | <0.00001               | 86                                    |
| Molecule                          |                |             |              |                        |                                      |
| Lipophilic                        | 7              | 0.51        | 0.46–0.57    | 0.16                   | 23                                    |
| Hydrophilic                       | 6              | 0.77        | 0.58–1.02    | 0.06                   | 45                                    |
| Simvastatin                       | 6              | 0.53        | 0.48–0.59    | 0.77                   | 0                                     |
| Atorvastatin                      | 5              | 0.54        | 0.45–0.64    | 0.56                   | 0                                     |
| Fluvastatin                       | 3              | 0.83        | 0.48–1.44    | 0.33                   | 10                                    |
| Pravastatin                       | 5              | 0.77        | 0.57–1.05    | 0.71                   | 0                                     |
| Rosuvastatin                      | 4              | 0.55        | 0.37–0.83    | 0.55                   | 0                                     |
| Lovastatin                        | 2              | 0.30        | 0.15–0.62    | 0.36                   | 0                                     |
| Pitavastatin                      | 2              | 0.36        | 0.17–0.75    | 0.54                   | 0                                     |
| Cerivastatin                      | 2              | 0.61        | 0.26–1.42    | 0.34                   | 0                                     |
| Cumulative defined daily dose     |                |             |              |                        |                                      |
| \( \leq 365 \)                    | 6              | 0.55        | 0.47–0.65    | 0.04                   | 47                                    |
| >365                              | 4              | 0.38        | 0.28–0.50    | 0.44                   | 0                                     |
| Statin combined with aspirin      |                |             |              |                        |                                      |
| Statin and aspirin                | 2              | 0.57        | 0.40–0.81    | <0.00001               | 92                                    |
| Just aspirin                      | 4              | 0.86        | 0.65–1.14    | 0.02                   | 69                                    |
| Time period                       |                |             |              |                        |                                      |
| \( \leq 10 \) years               | 10             | 0.65        | 0.52–0.80    | <0.00001               | 92                                    |
| >10 years                         | 18             | 0.54        | 0.48–0.61    | 0.0003                 | 62                                    |

\(^{a}P \leq 0.10, \) explains source of heterogeneity between groups.

---

**Table 4: Sensitivity analysis to examine sources of heterogeneity observed in summary estimate.**

| Sensitivity analysis               | No. of studies | Adjusted OR | 95% CI       | Tests of heterogeneity  |
|-----------------------------------|----------------|-------------|--------------|-------------------------|
|                                   |                |             |              |  \( P \) | \( I^2 (%) \) | Heterogeneity between groups (\( P \)) |
| Sensitivity analysis (to examine source of heterogeneity seen in observational studies) |                |             |              |                        |                                      |
| Study quality                     |                |             |              |                        |                                      |
| High quality                      | 15             | 0.58        | 0.48–0.70    | <0.00001               | 94                                    |
| Low quality                       | 13             | 0.56        | 0.45–0.70    | <0.00001               | 79                                    |
| Study design                      |                |             |              |                        |                                      |
| Cohort                            | 18             | 0.59        | 0.48–0.72    | <0.00001               | 91                                    |
| Case-control                      | 10             | 0.54        | 0.42–0.70    | <0.00001               | 92                                    |
| Sensitivity analysis (to examine source of heterogeneity seen in high-quality observational studies) |                |             |              |                        |                                      |
| Study location                    |                |             |              |                        |                                      |
| Asian                             | 5              | 0.50        | 0.42–0.59    | 0.13                   | 44                                    |
| Western                           | 10             | 0.64        | 0.52–0.79    | <0.00001               | 92                                    |

\(^{a}P \leq 0.10, \) source of heterogeneity between groups.

---

In human hepatocarcinoma cell lines and aflatoxin-induced liver cancer transgenic animal models, atorvastatin has been shown to block phosphorylation and activation of Myc through HMG-CoA reductase-dependent pathways, thereby inhibiting tumorigenesis and tumor growth [57]. Statins can induce cell apoptosis, but the underlying pathway has not been fully confirmed. Statins may block the
cell cycle in the G0/G1 phase by interfering with the Ras/Raf/MEK/ERK signaling pathways or regulating cyclin-dependent kinases and their inhibitors [67]. It is worth noting the results of the study by Sutter et al. showed that the apoptosis of liver cancer cells induced by statins may be related to reduction in DJM and activation of caspases 8 and 3 [68].

In addition, Raf-MEK-ERK and PI3K-AKT-mTOR pathways are necessary for cancer cell survival. Statin-induced isoprene can not only reduce the activation of these two channels but also inhibit HCV replication [69]. Therefore, the enhancement by statins of the human virological response to peginterferon and ribavirin therapy may be related to improvements in the antiviral activity of HCV polymerase and protease inhibitors [70, 71].

The chemopreventive connection between statins and liver cancer is obvious among Asians but not among Western populations, based on the data from high-quality observational studies. We can speculate that the difference may be related to the different etiologies of liver cancer in the two regions.

Eighty percent of HCC cases occur in East Asia and sub-Saharan Africa [1]. We know that the main risk factors for liver cancer in the Western population are chronic HCV infection and fatty liver disease [72]. However, in Asia, chronic HBV infection is the primary risk factor [73].

HBV participates in the occurrence and development of HCC through direct and indirect mechanisms, and the HBV protein HBx plays a major role. Compared with liver cancer caused by other risk factors, HBV-related liver cancer has a higher chromosomal mutation rate, p53 gene mutation rate, and inactivation mutation rate; fetal liver/liver progenitor cell genes are often overexpressed, and the Wnt/b-catenin pathway is often activated, but the mutation rate of activated b-catenin is low [74]. Similarly, the HCV core protein promotes cell proliferation by inhibiting E2F-1, Rb phosphorylation, p53 protein, and p21 protein kinase inhibitors [75]. The HCV core protein can also activate the Wnt/b-catenin cascade to promote cell proliferation [76]. In addition, the HCVNS3 protein, which is a multifunctional protein, can bind to p53 to inhibit its activity, thereby inhibiting the transcription of p21, leading to uncontrolled cell proliferation and accelerating the occurrence and development of liver cancer [77]. Studies have found that statins can counteract these effects and inhibit tumor growth.

In Asian populations, statins mainly work by antagonizing the carcinogenic effects of HBV, while in Western populations, the mechanism is unclear. The results of our analysis also confirmed the difference in this benefit between Eastern and Western populations and the possible source of the difference. When we analyzed the subgroups of HBV-related liver cancer and HCV-related liver cancer, the results showed that statins had protective effects against both types of liver cancer, especially HBV-related liver cancer (Table 3). Increasing evidence shows that diabetes and/or insulin resistance are intrinsically linked to the progression of liver disease in patients with chronic hepatitis C, and statins may exert their antitumor effects through antiinfective mechanisms.

Further analysis showed that the chemopreventive effect of statins is more significant in patients with chronic liver disease than in the general population. Patients with chronic liver disease are at high risk of HCC. The chemopreventive effect of statins is more likely to yield positive results in people with chronic liver disease.

After further analysis of the dosage of statins, it was found that higher cumulative doses had greater chemopreventive effects than lower doses of statins (Table 3).

In a cohort study of HCV-positive patients, Tsan et al. confirmed the chemopreventive effect of statins against liver cancer [23]. Compared with patients who did not use statins, AHR for the cumulative dose over 28–89 days was 0.66, that for 90–180 days was 0.47, and that for more than 180 days was 0.33; the P values were all less than 0.001. Simon et al. [25] used a similar dose division method to Tsan et al. and drew the same conclusion in an HCV-positive patient cohort (AHR = 0.85 vs. 0.48 vs. 0.51). Kim et al. [26] also showed that the adjusted ORs were 0.56, 0.41, and 0.30 for patients who had cumulative defined doses of 180–365, 365–720, and greater than 720 daily doses, respectively. In their study involving a cohort of HBV-positive patients, Goh et al. confirmed that continuous high-dose statin therapy exerted a relatively stronger chemopreventive effect against liver cancer [28]. The AHRs were 0.63 (0.31–1.29), 0.51 (0.21–1.25), 0.32 (0.07–1.36), and 0.17 (0.06–0.48) for patients who had 28–365, 366–730, 731–1095, and more than 1095 cumulative daily defined doses, respectively. In the analysis of individual patient data from 5 randomized controlled trials conducted by the CTT collaborative group, compared with "less" use of statins, "more" use of statins had a statistically significant chemopreventive effect [48].

Our research showed that lipophilic statins had a chemopreventive effect against liver cancer, while hydrophilic statins did not (Table 3). As has been observed in previous individual studies, lipophilic statins (simvastatin, atorvastatin, fluvastatin, lovastatin, pitavastatin, and cerivastatin) are more effective at preventing liver cancer than hydrophilic statins (49% vs. 23%). It can be speculated that the reason lipophilic statins (such as lovastatin and simvastatin) have stronger chemoprotective effects is that they have better fat solubility and membrane permeability than hydrophilic statins (such as pravastatin). This theory is supported by our results to a certain extent. The study of Li et al. [78] also showed that the use of lipophilic statins is associated with a lower risk of HCC in patients with HBV or HCV infection, but has nothing to do with hydrophilic statins, which coincides with our results. Further analysis of different types of statins found that lovastatin has the best protective effect, while fluvastatin has no protective effect (Table 3). This conclusion is different from the study of Zhou et al. [51]. Their study shows that fluvastatin has the best protective effect. Considering that their study only included 5 articles, our conclusion is more reliable because the conclusion is more stable. In addition, the study by Facciorusso et al. showed that both simvastatin (OR, 0.69; 95% CI: 0.42–1.15) and rosuvastatin (OR, 0.53; 95% CI: 0.04–6.38) had no chemopreventive effect, which is contrary to our conclusion [54]. Our study shows that both simvastatin (OR, 0.53; 95%
CI: 0.48–0.59) and rosuvastatin (OR, 0.55; 95% CI: 0.37–0.83) have chemopreventive effects. Considering that the study by Facciorusso et al. included only two studies for both types of statin analysis, the lack of representativeness due to the small number of included studies may cause errors.

Our study showed that coadministration of aspirin did not significantly improve the preventive effect of statins on liver cancer (OR, 0.57 vs. 0.58), and aspirin alone had no preventive effect on liver cancer (OR, 0.86; 95% CI: 0.65–1.14). This conclusion contradicts previous studies. Studies by Luca et al. have shown that low-dose aspirin has a preventive effect on a variety of malignancies, including hepatocellular carcinoma [79]. The reason for this contradiction may be that our study included fewer studies, thus making the conclusions less reliable and representative.

Interestingly, we analyzed the relationship between follow-up time and HCC incidence, and the results were different from our assumptions. According to the general assumption, with the increase of follow-up time, the incidence of liver cancer will also increase. However, our analysis showed that the incidence of liver cancer was lower in the population with a follow-up period of more than 10 years than in the population with a follow-up period of fewer than 10 years (OR, 0.54 vs. 0.65). Such results demonstrate the effect of statins in preventing liver cancer from another aspect because with the increase of follow-up time, the time of taking statins will theoretically increase, thus improving its prevention effect of liver cancer, and the incidence of liver cancer will decrease accordingly.

Alcohol is a recognized carcinogen and is closely related to the occurrence of liver cancer [80]. Therefore, we also attempted to further analyze the potential impact of alcohol intake on the protective effect of statins on hepatocarcinogenesis. Of the 28 observational studies included, 13 included alcohol intake in the population, 8 of which were cohort studies. Data on alcohol intake were presented in aggregated demographic characteristics, so we were unable to extract specific values for alcohol intake and the risk of statins and liver cancer, so we could not perform a meta-analysis of their potential risk. However, a previous study by Wei-Chie et al. showed that statin use may reduce the risk of HCC in alcohol abusers [81]. Therefore, we also have reasons to infer that statin is a protective factor for liver cancer in alcohol abusers and hope that more high-quality RCT studies can be carried out in the future to facilitate the exploration of this issue.

This analysis mainly included observational studies. The number of people included in observational studies accounted for 96.99% of the total number of patients, and a significant chemopreventive effect was observed in observational studies (OR, 0.57, 95% CI: 0.49–0.66). RCTs accounted for a relatively small proportion of the included studies, and no obvious chemopreventive effect was observed (OR, 0.95, 95% CI: 0.62–1.45).

We should consider the results of the RCTs included in the context. Most of the RCTs involved Western population, and the different etiologies of liver cancer may have weakened the chemopreventive effect of statins. Moreover, long-term RCTs with large populations are difficult to conduct, and there was a risk of loss to follow-up. This should also be considered.

In addition, the results of this study are significantly different from those of Yi et al. [27]. Research by Yi et al. showed that the lower risk of hepatocellular carcinoma is related to higher cholesterol levels and not the use of statins. In their study, after adjusting cholesterol, the protective effect of statins disappeared (HR = 1.16, 95% CI = 0.80–1.69). Since cholesterol levels are significantly negatively correlated with the occurrence of liver cancer, the adjustment of cholesterol before and after the study is also very important.

4.1. Strength and Limitations. This study included more than 4.9 million participants, which is the largest study we have known so far. Compared with the previous meta-analysis, we focused on the relationship between the use of statins and the risk of liver cancer. Due to the inclusion of a large number of studies, the stability and persuasiveness of the results have increased. In addition, this study conducted a comprehensive discussion on potential confounding factors and demonstrated in detail the study design, study area, research quality, virus type, population characteristics, and cumulative defined daily dose. These arguments explain to a certain extent that the overall heterogeneity of the article comes from high-quality Western observational research and provide an improved direction for subsequent research design.

In addition to the limitations formerly mentioned, other limitations deserve further consideration. First, the incidence of cardiovascular events in people with chronic liver disease is correspondingly higher [82], so they may choose to use more statins, which will cause deviation. Second, although the publication bias of this article is low, it is still worthy of further exploration because negative research related to liver cancer by statins may be more difficult to publish. Third, the studies included were mostly observational (cohort studies and case-control studies), and there were few RCTs. The main reason is that it is very difficult to implement large-scale RCTs. In addition, the RCTs included in this analysis were mainly from Western countries, which may have affected the results. Finally, differences in language, lifestyle, social class, education level, and sample size among studies may also have resulted in bias. Fourth, in the subgroup analysis of different types of statins, due to insufficient relevant research, the number of literature included in each group is relatively small. Therefore, it is necessary to carry out relevant research on different types of statins in the future, which will have a positive significance for clinical treatment.

5. Conclusion

Overall, this meta-analysis showed that the chemopreventive effect of statins on liver cancer is more pronounced in Asian populations than in other populations. Due to the differences in the etiology of liver cancer between Eastern and Western populations, we should carefully judge the benefits of statins in Western populations. At present, the relevant
large-scale RCTs have mainly been performed in Western countries. In the future, it is necessary to carry out RCTs in areas with high burdens of liver cancer (such as East Asia). The chemopreventive effects of statins require their long-term use, and the burden imposed by the cumulative cost may have a certain passive influence on their clinical use. However, in areas with high burdens of liver cancer, the preventive use of statins should be considered.

Abbreviations

BMI: Body mass index
CDDDs: Cumulative defined daily doses
DM: Diabetes
HBV: Hepatitis B virus
HCC: Hepatocellular carcinoma
HCV: Hepatitis C virus
HR: Hazard ratio
HMG-CoA: 3-Hydroxy-3-methylglutaryl CoA
MOOSE: Meta-analysis Of Observational Studies in Epidemiology
OR: Odds ratio
PPIs: Proton pump inhibitors
PRISMA: Preferred Reporting Items for Systematic Review and Meta-Analysis
RCT: Randomized controlled trials
ROS: Reactive oxygen species.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Yikai Wang and Shuangsoo Dang conceived and designed this research. Yikai Wang performed statistical analysis and wrote the first draft of the manuscript. Yikai Wang, Wenjun Wang, and Muqi Wang conducted literature search and literature screening. Yikai Wang and Juanjuan Shi assessed the risk of bias in the study. Xiaoli Jia assisted in statistical analysis. Shuangsoo Dang is responsible for the overall content as the guarantor.

Acknowledgments

This article was supported by the Key Research and Development Program-Social Development of Shaanxi Province (2020SF-063) and the Fundamental Research Funds for the Central Universities (xjh012019063).

References

[1] J. Ferlay, I. Soerjomataram, R. Dinshet et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E366, 2015.
[2] V. Augusto and M. Llovet Josep, “Liver cancer in 2013: mutational landscape of HCC—the end of the beginning,” Nature Reviews Clinical Oncology, vol. 11, pp. 73–74, 2014.
[3] F. Bray, J. Ferlay, and I. Soerjomataram, R. L Siegel, L. A. Torre, and A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: A Cancer Journal for Clinicians, vol. 68, pp. 394–424, 2018.
[4] S. Pisanti, P. Picardi, E. Ciaglia, A. D’Alessandro, and M. Bifulco, “Novel prospects of statins as therapeutic agents in cancer,” Pharmacological Research, vol. 88, pp. 84–98, 2014.
[5] C. Baigent, A. Keech, P. M. Kearney et al., “Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins,” Lancet, vol. 366, pp. 1267–1278, 2005.
[6] K. K. Chan, A. M. Oza, and L. L. Siu, “The statins as anticancer agents,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol. 9, no. 1, pp. 10–19, 2003.
[7] S.-G. Aleksandra, K.-B. Bożenna, G. Tomasz, and K. Krawczak, “Statins and cancers,” Contemporary Oncology, vol. 19, pp. 167–175, 2015.
[8] D. E. Dawe, X. Ye, P. Czykowskio et al., “The effect of statin use on the incidence of prostate cancer: a population-based nested case-control study,” International Journal of Cancer, vol. 143, no. 1, pp. 190–198, 2018.
[9] A. N. Ananthakrishnan, A. Cagan, T. Cai et al., “Statin use is associated with reduced risk of colorectal cancer in patients with inflammatory bowel diseases,” Clinical Gastroenterology and Hepatology, vol. 14, no. 7, pp. 973–979, 2016.
[10] M. Shi, H. Zheng, B. Nie, W. Gong, and X. Cui, “Statin use and risk of liver cancer: an update meta-analysis,” BMJ Open, vol. 4, no. 9, Article ID e005399, 2014.
[11] H.-F. Chiu, S.-C. Ho, C.-C. Chen, and C.-Y. Yang, “Statin use and the risk of liver cancer: a population-based case-control study,” American Journal of Gastroenterology, vol. 106, no. 5, pp. 894–898, 2011.
[12] S. Singh, P. P. Singh, A. G. Singh, M. H. Murad, and W. Sanchez, “Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis,” Gastroenterology, vol. 144, no. 2, pp. 323–332, 2013.
[13] Y. Liu, W. Tang, J. Wang et al., “Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies,” Cancer Causes & Control, vol. 25, no. 2, pp. 237–249, 2014.
[14] M.-F. Demierre, P. D. R. Higgins, S. B. Gruber, E. Hawk, and S. M. Lippman, “Statins and cancer prevention,” Nature Reviews Cancer, vol. 5, no. 12, pp. 930–942, 2005.
[15] S. Zeichner, C. G. Mihos, and O. Santana, “The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in malignancies: a comprehensive review,” Journal of Cancer Research and Therapeutics, vol. 8, pp. 176–183, 2012.
[16] A. Lonardo and P. Loria, “Potential for statins in the chemoprevention and management of hepatocellular carcinoma,” Journal of Gastroenterology and Hepatology, vol. 27, no. 11, pp. 1654–1664, 2012.
[17] S. Friis, A. H. Poulsen, S. P. Johnsen et al., “Cancer risk among statin users: a population-based cohort study,” International Journal of Cancer, vol. 114, no. 4, pp. 643–647, 2005.
[18] D. F. Stroup, J. A. Berlin, S. C. Morton et al., “Meta-analysis of observational studies in epidemiology: a proposal for reporting,” JAMA, vol. 283, no. 15, pp. 2008–2012, 2000.
of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy," PLoS One, vol. 7, no. 1, Article ID e29849, 2012.

[49] S. Sato, W. Ajiki, T. Kobayashi, N. Awata, and PCS Study Group, "Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study," Journal of Epidemiology, vol. 16, no. 5, pp. 201–206, 2006.

[50] J. Wang and X. Li, "Impact of statin use on the risk and prognosis of hepatocellular carcinoma: a meta-analysis," European Journal of Gastroenterology & Hepatology, vol. 33, 2021.

[51] Y. Y. Zhou, G. Q. Zhu, Y. Wang et al., "Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma," Oncotarget, vol. 7, no. 16, pp. 21753–21762, 2016.

[52] D. Pradelli, D. Soranna, and L. Scotti, A. Zambon, A. Catapano, G. Mancia, C. La Vecchia, and G. Corrao, Statins and primary liver cancer: a meta-analysis of observational studies," European Journal of Cancer Prevention: The Official Journal of the European Cancer Prevention Organisation (ECP), vol. 22, pp. 229–234, 2013.

[53] Y. Chang, Q. Liu, Z. Zhou et al., "Can statin treatment reduce the risk of hepatocellular carcinoma? a systematic review and meta-analysis," Technology in Cancer Research & Treatment, vol. 19, Article ID 1533038209343881, 2020.

[54] A. Facciorusso, Abd El Aziz Mohamed, S. Singh et al., "Statin use decreases the incidence of hepatocellular carcinoma: an updated meta-analysis," Journal of Cancer, vol. 12, 2020.

[55] B. Relja, F. Meder, K. Wilhelm, D. Henrich, I. Marzi, and M. Lehnhart, "Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells," International Journal of Molecular Medicine, vol. 26, pp. 735–741, 2010.

[56] W. Zhang, J. Wu, L. Zhou, H. Y. Xie, and S. S. Zheng, "Fluvastatin, a lipophilic statin, induces apoptosis in human hepatocellular carcinoma cells through mitochondria-operated pathway," Indian Journal of Experimental Biology, vol. 48, pp. 1167–1174, 2010.

[57] Z. Cao, H. Fan-Minogue, D. I. Bellovin et al., "MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase," Cancer Research, vol. 71, no. 6, pp. 2286–2297, 2011.

[58] C. Y. Jeon, M. T. Goodman, and G. Cook-Wiens, V. Sundaram, Statin use and survival with early-stage hepatocellular carcinoma," Cancer Epidemiology Biomarkers & Prevention, vol. 25, no. 4, pp. 686–692, 2016.

[59] Y.-T. Tsan, C.-H. Lee, J.-D. Wang, and P.-C. Chen, "Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection," Journal of Clinical Oncology, vol. 30, no. 6, pp. 623–630, 2012.

[60] F. Giovanna, S. Tommaso, Z. Irene, and D. Francesco, "Hepatocellular carcinoma in cirrhosis: incidence and risk factors," Gastroenterology, vol. 127, pp. S35–S50, 2004.

[61] H. Takaaki, L. Friedman Scott, and Y. Hoshida, "Hepatic stellate cells as key target in liver fibrosis," Advanced Drug Delivery Reviews, vol. 121, pp. 27–42, 2017.

[62] L. W. Chong, Y. C. Hsu, T. F. Lee et al., "Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells," BMC Gastroenterology, vol. 15, p. 22, 2015.

[63] B. Kwak, F. Mulhaupt, S. Myit, and F. Mach, "Statins as a newly recognized type of immunomodulator," Nature Medicine, vol. 6, no. 12, pp. 1399–1402, 2000.

[64] L. Bakiri, R. Hamacher, and O. Graña, A Guio-Carríon, R. Campos-Olivas, L. Martinez et al., Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation," Journal of Experimental Medicine, vol. 214, pp. 1387–1409, 2017.

[65] P. A. Farazi and R. A. DePinho, "Hepatocellular carcinoma pathogenesis: from genes to environment," Nature Reviews Cancer, vol. 6, no. 9, pp. 674–687, 2006.

[66] C. M. Shachaf, A. M. Kopeiman, C. Arvanitis et al., "MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer," Nature, vol. 431, no. 7012, pp. 1112–1117, 2004.

[67] M. Jakobisiak and J. Golab, "Potential antitumor effects of statins (review)," International Journal of Oncology, vol. 23, pp. 1055–1069, 2003.

[68] A. P. Sutter, K. Maaser, M. Höpfner, A. Huether, D. Schuppian, and H. Scherübäi, "Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors: synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor," Journal of Hepatology, vol. 43, no. 5, pp. 808–816, 2005.

[69] J. Ye, C. Wang, R. Sumpter, M. S. Brown, J. L. Goldstein, and M. Gale, "Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation," Proceedings of the National Academy of Sciences, vol. 100, no. 26, pp. 15865–15870, 2003.

[70] L. Delang, J. Paeshuyse, I. Vliegen et al., "Statins potentiate their vitoanti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development," Hepatology, vol. 50, no. 1, pp. 6–16, 2009.

[71] S. A. Harrison, L. Rossaro, K.-Q. Hu et al., "Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy," Hepatology, vol. 52, no. 3, pp. 864–874, 2010.

[72] A. Tang, O. Hallouch, V. Chernyak, A. Kamaya, and C. B. Sirlin, "Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis," Abdominal Radiology, vol. 43, no. 1, pp. 13–25, 2018.

[73] S. Evangelista, M. Margherita, A. Russo, C. Nicola, and C. Caterina, "Epidemiological and etiological variations in hepatocellular carcinoma," Infection, vol. 48, pp. 7–17, 2020.

[74] M. Leverroo, J. Zucman-Rossi, and Z.-R. Jessica, "Mechanisms of HBV-induced hepatocellular carcinoma," Journal of Hepatology, vol. 64, pp. S84–S101, 2016.

[75] C. Y. Park, S. H. Choi, S. M. Kang et al., "Nonstructural 5A protein activates β-catenin signaling cascades: implication of hepatitis C virus-induced liver pathogenesis," Journal of Hepatology, vol. 51, no. 5, pp. 853–864, 2009.

[76] C. Kazuaki and H. C. Nelson, "Hepatitis C virus: how genetic variability affects pathobiology of disease," Journal of Gastroenterology and Hepatology, vol. 26, pp. 83–95, 2011.

[77] X. Zhang, S. Liu, T. Hu, S. Liu, Y. He, and S. Sun, "Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression," Hepatology, vol. 50, no. 2, pp. 490–499, 2009.

[78] X. Li, L. Sheng, L. Liu, Y. Hu, Y. Chen, and L. Lou, "Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis," BMC Gastroenterology, vol. 20, no. 1, p. 98, 2020.

[79] I. Luca, T. Francesco, T. Matteo et al., "Beneficial prognostic effects of aspirin in patients receiving sorafenib for hepatocellular carcinoma: a tale of multiple confounders," Journal of Cancer, vol. 13, 2021.
[80] S.-Y. Liu, I.-T. Tsai, and H. Yin-Chou, "Alcohol-related liver disease: basic mechanisms and clinical perspectives," International Journal of Molecular Sciences, vol. 22, 2021.

[81] C. Wei-Che, S. Jia-Chi, Y. Yao-Hsu, C. V. Chin-Hung, and P. Pau-Chung, "Statins and the risks of decompensated liver cirrhosis and hepatocellular carcinoma determined in patients with alcohol use disorder," Drug and Alcohol Dependence, vol. 228, Article ID 109096, 2021.

[82] G. Targher, L. Bertolini, and R. Padovani, "Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C," Journal of Hepatology, vol. 46, pp. 1126–1132, 2007.